Agios Pharmaceuticals (NASDAQ:AGIO) Posts Quarterly Earnings Results, Misses Expectations By $0.09 EPS

Agios Pharmaceuticals (NASDAQ:AGIO) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing the consensus estimate of ($1.60) by ($0.09), Briefing.com reports. Agios Pharmaceuticals had a negative net margin of 1,165.69% and a negative return on equity of 44.84%. The firm had revenue of $8.60 million for the quarter, compared to the consensus estimate of $9.34 million. During the same period last year, the business earned ($1.51) EPS. Agios Pharmaceuticals’s revenue was up 28.4% on a year-over-year basis.

Agios Pharmaceuticals Stock Performance

NASDAQ AGIO traded down $0.54 on Friday, reaching $43.96. The company had a trading volume of 563,979 shares, compared to its average volume of 595,648. The firm’s 50 day moving average price is $44.48 and its 200 day moving average price is $34.47. Agios Pharmaceuticals has a 12 month low of $19.80 and a 12 month high of $50.35.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on AGIO shares. JPMorgan Chase & Co. restated a “neutral” rating and issued a $46.00 target price on shares of Agios Pharmaceuticals in a report on Thursday, June 13th. Royal Bank of Canada lifted their price target on shares of Agios Pharmaceuticals from $53.00 to $55.00 and gave the stock an “outperform” rating in a research note on Friday. StockNews.com upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, July 11th. The Goldman Sachs Group lifted their price target on shares of Agios Pharmaceuticals from $33.00 to $53.00 and gave the stock a “neutral” rating in a research note on Tuesday, June 4th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Monday, June 17th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $51.33.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.